Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
- Partnership with tech giants Microsoft and Databricks provides advanced AI and cloud computing capabilities
- Two proprietary AI technologies (PredicTcell and AdapTcell) with patents pending could accelerate drug development
- AI integration expected to reduce clinical development costs and timelines
- Company expanding headquarters to accommodate AI team growth
- Internal valuation of AI assets still pending, creating uncertainty about their worth
- Additional capital may be needed to execute business plan
- Significant competition in healthcare AI space from established players
- Early stage of AI implementation with unproven commercial success
Insights
Tevogen's AI initiative establishes strategic tech partnerships and develops proprietary algorithms to accelerate immunotherapy development and reduce costs.
Tevogen's announcement of its Tevogen.AI initiative represents a significant integration of artificial intelligence into its immunotherapy development platform. The company has established two notable strategic partnerships: one with Microsoft providing cloud infrastructure and AI expertise, and another with Databricks for specialized data engineering capabilities. These collaborations give Tevogen access to enterprise-grade AI resources without building this infrastructure from scratch.
The company has developed two proprietary AI technologies with patents pending:
- PredicTcell: A prediction engine for identifying immunologically active peptide complexes and their T cell receptor interactions. This system processes a terabyte-scale database of millions of protein-peptide interactions spanning multiple diseases.
- AdapTcell: Algorithms focused on decoding HLA-T cell interactions to enhance understanding of immune responses, particularly valuable in areas with limited existing data.
The strategic value lies in how these technologies could transform Tevogen's core ExacTcell platform by accelerating target identification and pre-clinical processes. If successful, this approach could significantly compress development timelines and reduce costs—two critical factors in immunotherapy development where both time and capital expenditures are substantial hurdles.
Tevogen is backing this initiative with physical infrastructure expansion, creating dedicated facilities for its AI team. The company's ambition extends beyond improving its current pipeline, with stated plans to apply these technologies across multiple healthcare sectors, suggesting potential for diversified revenue streams beyond their core therapeutic focus.
While the press release indicates an internal valuation of these assets is forthcoming, the market will need concrete metrics to properly assess how these AI capabilities translate to competitive advantage and financial performance. The pending patent status of both technologies is noteworthy as IP protection will be crucial for maintaining any technological edge in this rapidly evolving field.
WARREN, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today provided stockholders with a detailed overview of its artificial intelligence initiative, Tevogen.AI™.
Tevogen.AI™ aims to integrate advanced machine learning and predictive modeling into Tevogen Bio’s proprietary ExacTcell™ technology to significantly enhance its target identification and pre-clinical processes, thereby strengthening the Company’s pipeline of innovative immunotherapies, accelerating clinical timelines, and substantially reducing development costs.
Tevogen.AI currently has two proprietary technologies, each with patents pending, and an internal valuation of these assets is forthcoming. The Company plans to expand its AI initiative with applications that extend well beyond Tevogen Bio. In preparation for this anticipated growth, Tevogen is expanding its headquarters to include dedicated facilities for Tevogen.AI’s team of data scientists and engineers.
Tevogen CEO, Dr. Ryan Saadi, commented, “Healthcare is one of the largest segments of our economy, projected to approach
Strategic Partnerships:
Microsoft (Nasdaq: MSFT): Provides industry-leading AI expertise, cloud computing infrastructure (Azure), and scientific resources to accelerate drug discovery processes.
Databricks: Supplies specialized data engineering and analytics capabilities to refine Tevogen’s AI models and enhance predictive accuracy.
Proprietary Tevogen.AI Technology:
PredicTcell™: AI tools capable of accurately predicting immunologically active peptide complexes and their interactions with T cell receptors, driving precision in immunotherapy treatments.
The PredicTcell platform is a collection of multiple algorithms which performs in-silico predictions for candidate selection across multiple diseases. It continually improves with each accurate prediction through model tuning and reinforcement, helping expand our understanding of T cell receptor bindings, and therefore shortening the in-vivo process and expanding Tevogen Bio’s pipeline. To date, Tevogen.AI has developed a continually expanding, terabyte-scale database that processes millions of protein and peptide interactions spanning numerous diseases and the human genome.
AdapTcell™: Algorithms to decode the interactions between human leukocyte antigens (HLA) and T cells.
AdapTcell is expected to significantly enhance Tevogen Bio’s understanding of immune responses and open new therapeutic avenues, especially in areas with minimal existing data. As our understanding of key interactions expand, AdapTcell built algorithms perform experiments unlocking insights into genetics and proteomics. The platform aims to expand upon the cross sections of genetics and protein interactions and build an HLA specificity map.
Tevogen.AI plans to expand into clinical trial patient identification using the information collected from its PredicTcell and AdapTcell platforms to drive efficiency, cost reduction and deliver targeted results.
Tevogen remains committed to transparent communication with its stockholders and will continue providing clear updates on the progress and achievements of Tevogen.AI.
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What are the main components of Tevogen's AI initiative?
How will Microsoft and Databricks contribute to Tevogen's AI development?
What is the purpose of Tevogen's PredicTcell technology?
How does Tevogen plan to use AI in clinical trials?
What is the market opportunity for Tevogen's AI initiative?
